InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
62,894.38
(
-0.49%
)
Post# of 84
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AC416

Send PM Follow Ignore
Followers 30
Posts 3024
Boards Moderated 0
Alias Born 09/29/2006

AC416

Re: None

Tuesday, 08/04/2009 10:52:08 PM

Tuesday, August 04, 2009 10:52:08 PM

Post# of 84
ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/ - Covidien (NYSE:COV - News), a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI - News), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act (PDUFA) for Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November 4, 2009.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up